World Hepatitis Day 2023: Are we close to the target?
作者信息
Hui Rex Wan-Hin, Fung James
机构信息
Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
Department of Medicine, School of Clinical Medicine; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong.
出版信息
Indian J Med Res. 2023 Jan;158(1):1-4. doi: 10.4103/ijmr.ijmr_1250_23.
Abstract
摘要
相似文献
1
World Hepatitis Day 2023: Are we close to the target?
Indian J Med Res. 2023 Jan;158(1):1-4. doi: 10.4103/ijmr.ijmr_1250_23.
2
Infective hepatitis: a problem of world health.
Br Med J. 1952 Jun 28;1(4773):1367-71. doi: 10.1136/bmj.1.4773.1367.
3
[World distribution of epidemic hepatitis (Botkin's disease)].
Vopr Virusol. 1956 May-Jun;1(3):3-11.
4
Viral hepatitis elimination: Towards a hepatitis-free world.
J Hepatol. 2022 Nov;77(5):1444-1447. doi: 10.1016/j.jhep.2022.06.034. Epub 2022 Jul 27.
5
[Prevention of virus hepatitis from the standpoint of present day research].
Offentl Gesundheitsdienst. 1955 Dec;17(9):331-8.
6
Post hoc, ergo propter hoc? Evaluating a Potential Increase in Childhood Severe Hepatitis in a Post-COVID World.
J Pediatric Infect Dis Soc. 2022 Aug 30;11(8):354-356. doi: 10.1093/jpids/piac054.
7
Hepatitis A in day-care centers. A community-wide assessment.
N Engl J Med. 1980 May 29;302(22):1222-7. doi: 10.1056/NEJM198005293022203.
8
The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination.
J Infect Dis. 2023 Sep 13;228(Suppl 3):S154-S159. doi: 10.1093/infdis/jiad104.
9
Hepatitis A infection in recent international adoptees and their contacts in Minnesota, 2007-2009.
Pediatrics. 2011 Aug;128(2):e333-8. doi: 10.1542/peds.2010-1840. Epub 2011 Jul 4.
10
Hepatitis A vaccines.
Wkly Epidemiol Rec. 2000 Feb 4;75(5):38-44.
引用本文的文献
1
Stakeholder perspectives and the challenges in implementing hepatitis C elimination policy in Pakistan.
Front Public Health. 2025 Jul 16;13:1540689. doi: 10.3389/fpubh.2025.1540689. eCollection 2025.
2
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?
Hepatol Int. 2025 Apr;19(2):304-314. doi: 10.1007/s12072-025-10785-8. Epub 2025 Feb 17.
3
MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on "Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan".
Clin Mol Hepatol. 2025 Jan;31(1):290-292. doi: 10.3350/cmh.2024.0630. Epub 2024 Aug 7.
本文引用的文献
1
Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy.
Expert Rev Gastroenterol Hepatol. 2023 May;17(5):443-450. doi: 10.1080/17474124.2023.2196405. Epub 2023 Apr 3.
2
Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023.
MMWR Recomm Rep. 2023 Mar 10;72(1):1-25. doi: 10.15585/mmwr.rr7201a1.
3
Global treatment rate and barriers to direct-acting antiviral therapy: A systematic review and meta-analysis of 146 studies and 1 760 352 hepatitis C virus patients.
Liver Int. 2023 Jun;43(6):1195-1203. doi: 10.1111/liv.15550. Epub 2023 Mar 8.
4
Global reporting of progress towards elimination of hepatitis B and hepatitis C.
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-342. doi: 10.1016/S2468-1253(22)00386-7. Epub 2023 Feb 8.
5
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.
Clin Mol Hepatol. 2023 Apr;29(2):217-229. doi: 10.3350/cmh.2022.0399. Epub 2022 Dec 28.
6
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey.
JHEP Rep. 2022 Sep;4(9):100531. doi: 10.1016/j.jhepr.2022.100531. Epub 2022 Jul 27.
7
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials.
Expert Opin Emerg Drugs. 2022 Jun;27(2):127-140. doi: 10.1080/14728214.2022.2074977. Epub 2022 May 15.
8
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415. doi: 10.1016/S2468-1253(21)00472-6. Epub 2022 Feb 16.
9
Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
Lancet Glob Health. 2022 Feb;10(2):e278-e287. doi: 10.1016/S2214-109X(21)00517-9.
10
Hepatitis C virus micro-elimination: Where do we stand?
World J Gastroenterol. 2021 Apr 28;27(16):1728-1737. doi: 10.3748/wjg.v27.i16.1728.
Zotero 插件